Lv3
300 积分 2025-03-25 加入
Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational study
9天前
已完结
A Phase IB Trial of Autologous Cytokine‐Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death‐1, plus Chemotherapy in Patients with Advanced Non‐Small‐Cell Lung Cancer
10天前
已完结
P1.01-65 PII of Pemetrexed or Pemetrexed Plus Bevacizumab for Previously Untreated Elderly (>=75) Non-Squamous NSCLC (LOGIK1201)
12天前
已完结
Anlotinib combined with pemetrexed and carboplatin as first-line treatment in driver-gene negative advanced non-squamous non-small cell lung cancer: ALTER L012
12天前
已完结
ocetaxel combined with Lobaplatin as a second-line treatment for advanced non-small cell lung cancer: an observation of short-term efficacy
12天前
已完结
Algorithme thérapeutique des CBNPC sans mutation addictive
12天前
已关闭
SC23.04 Cooperative Groups in China: The CSCO Experience
14天前
已完结
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC
14天前
已完结
Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial
14天前
已完结
Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial
14天前
已完结
皖公网安备34019202002308
